Levetiracetam/phenytoin/primidone Reactions 1680, p202 - 2 Dec 2017 Suicidal ideation and increased irritability: 2 case reports In a case series, a 79-year-old man developed suicidal ideation and increased irritability during treatment with primidone, and a 76-year-old woman developed suicidal ideation during treatment with levetiracetam and phenytoin [routes and dosages not stated]. Case 1: A 79-year-old man was admitted following a serious suicide attempt. He reported taking 30 pills of an unspecified drug starting with "p" [complete name of the drug not stated]. However, as nothing happened, he attempted suicide by cutting his wrist twice with a knife. His brother found him half- an-hour following the event. Four days prior to the admission, he was started on a treatment with primidone for tremor. He reported feeling increasingly irritable for the past two days. On admission, his primidone therapy was discontinued. He continued to feel non-suicidal with a broad affect. Case 2: A 76-year-old woman, who had a long history of epilepsy, was admitted following a suicide attempt by cutting her both wrists deeply. The cuts were deep and required tendon repair. She reported that she felt "it was the right thing to do" at the moment, and also felt acutely depressed after reading about her medication list and the list of their side effects. Her son-in-law found her four hours following the attempt. One day prior to the admission, she was started on a treatment with levetiracetam. Prior to that, she was on phenytoin therapy for over 30 years to treat epilepsy. One the day following the event, she had a complete resolution of suicidal ideation, and reported having a better mood. Author comment: "Here we present two cases of suicidality and their correlation with [antiepileptic drugs]." Gulwadi A, et al. Case series demonstrating risk of suicidality with antiepileptic drugs-suicide attempt after 4 days of primidone and 1 day of levetiracetam use. CNS Spectrums 21: 120, No. 1, Feb 2016. Available from: URL: http:// doi.org/10.1017/S1092852915000905 [abstract] - USA 803284797 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial